A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) — Stella
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
United States
Stanford Cancer Institute, Palo Alto, California
Moffitt Cancer Cancer Center, Tampa, Florida
University of Kansas Medical Center, Kansas City, Kansas
Massachusetts General Hospital, Boston, Massachusetts
Dana Farber Cancer Institute, Boston, Massachusetts
University of Michigan, Ann Arbor, Michigan
Washington University School of Medicine, St Louis, Missouri
David H. Koch Center for Cancer Care at Memorial Sloan Kettering, New York, New York
Icahn School of Medicine at Mount Sinai, New York, New York
Levine Cancer Institute, Charlotte, North Carolina
University of Cincinnati, Cincinnati, Ohio
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio